Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.

被引：0
|
作者：
Massard, Christophe
Penttinen, Heidi
Bono, Petri
Vjaters, Egils
Lietuvietis, Vilnis
Tammela, Teuvo L. J.
Vuorela, Annamari
Nykanen, Pirjo
Pohjanjousi, Pasi
Fizazi, Karim
机构：
[1] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[2] Univ Helsinki, Cent Hosp, Ctr Canc, Helsinki, Finland
[3] P Stradins Clin Univ Hosp, Riga, Latvia
[4] Riga East Univ Hosp, Riga, Latvia
[5] Tampere Univ Hosp, Tampere, Finland
[6] Orion Corp Orion Pharma, Espoo, Finland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.230
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
230
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naive metastatic castration-resistant prostate cancer in Japan
    Okumura, Hiroyuki
    Inoue, Sachie
    Naidoo, Shevani
    Holmstrom, Stefan
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (08) : 1319 - 1329
  • [32] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1032 - 1040
  • [33] EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Shore, Neal
    Rathkopf, Dana
    Smith, Matthew R.
    de Bono, Johann S.
    Logothetis, Christopher
    de Souza, Paul
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott
    Fradet, Yves
    Griffin, Thomas
    Park, Youn C.
    Kheoh, Thian
    Small, Eric J.
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    JOURNAL OF UROLOGY, 2014, 191 (04): : E764 - E764
  • [34] Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
    Vjaters, E.
    Fizazi, K.
    James, N. D.
    Tammela, T. L.
    Matsubara, N.
    Priou, F.
    Beuzeboc, P.
    Lesimple, T.
    Bono, P.
    Kataja, V
    Garcia, J. A.
    Protheroe, A.
    Aspegren, J.
    Joensuu, H.
    Kuss, I
    Thiele, S.
    Fiala-Buskies, S.
    Jones, R. H.
    EUROPEAN UROLOGY, 2022, 81 : S786 - S787
  • [35] Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
    Jones, Robert Hugh
    Fizazi, Karim
    James, Nicholas D.
    Tammela, Teuvo L.
    Matsubara, Nobuaki
    Priou, Frank
    Beuzeboc, Philippe
    Lesimple, Thierry
    Bono, Petri
    Kataja, Vesa
    Garcia, Jorge A.
    Protheroe, Andrew
    Shore, Neal
    Aspegren, John
    Joensuu, Heikki
    Kuss, Iris
    Fiala-Buskies, Sabine
    Vjaters, Egils
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (04) : 786 - 789
  • [36] Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09)
    Rothermundt, Christian
    Hayoz, Stefanie
    Templeton, Arnoud J.
    Winterhalder, Ralph
    Strebel, Raeto T.
    Baertschi, Daniela
    Pollak, Michael
    Lui, Lillianne
    Endt, Kathrin
    Schiess, Ralph
    Rueschoff, Jan H.
    Cathomas, Richard
    Gillessen, Silke
    EUROPEAN UROLOGY, 2014, 66 (03) : 468 - 474
  • [37] LONG-TERM SAFETY AND ANTITUMOR ACTIVITY OF ODM-201 IN CHEMOTHERAPY AND CYP17-INHIBITOR NAIVE PATIENTS FROM THE ARADES AND THE ARAFOR TRIALS
    Shore, Neal
    Tammela, Teuvo
    Massard, Christophe
    Bono, Petri
    Aspegren, John
    Mustonen, Mika
    Fizazi, Karim
    JOURNAL OF UROLOGY, 2016, 195 (04): : E762 - E763
  • [38] Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction
    Cindolo, Luca
    Natoli, Clara
    De Nunzio, Cosimo
    De Tursi, Michele
    Valeriani, Maurizio
    Giacinti, Silvana
    Micali, Salvatore
    Rizzo, Mino
    Bianchi, Giampaolo
    Martorana, Eugenio
    Scarcia, Marcello
    Ludovico, Giuseppe Mario
    Bove, Pierluigi
    Laudisi, Anastasia
    Selvaggio, Oscar
    Carrieri, Giuseppe
    Bada, Maida
    Castellan, Pietro
    Topazio, Luca
    Boccasile, Stefano
    Ditonno, Pasquale
    Chiodini, Paolo
    Schips, Luigi
    CLINICAL GENITOURINARY CANCER, 2017, 15 (05) : 520 - 525
  • [39] Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial
    Zhou, Tie
    Qin, Shengfei
    Xu, Weidong
    Tang, Shouyan
    Chen, Guanghua
    Li, Song
    Hou, Jianguo
    Gao, Xu
    Shi, Guowei
    Sun, Zhongquan
    Jin, Jie
    Chen, Lijun
    Sun, Weibing
    Liu, Ben
    Wang, Jingen
    Meng, Qinggui
    Wang, Dongwen
    Hu, Zhiquan
    He, Dalin
    Yang, Yong
    Song, Xishuang
    Fu, Cheng
    Wang, Yinhuai
    Ye, Dingwei
    Zhang, Wei
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 792 - 802
  • [40] Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
    Graff, J. N.
    Baciarello, G.
    Armstrong, A. J.
    Higano, C. S.
    Iversen, P.
    Flaig, T. W.
    Forer, D.
    Parli, T.
    Phung, D.
    Tombal, B.
    Beer, T. M.
    Sternberg, C. N.
    ANNALS OF ONCOLOGY, 2016, 27 (02) : 286 - 294
12345